View Clinical Trial (Medical Research Study)
Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients
| City: |
|
Salt lake City |
| State: |
|
Utah |
| Zip Code: |
|
84113 |
| Conditions: |
|
Single Ventricle |
| Purpose: |
|
This pilot study is aimed at assessing the short-term effects of Tadalafil on the
hemodynamic response to exercise and exercise capacity in patients with Fontan circulation.
Data regarding effect size and drug tolerability will be used in the design of a randomized
multicenter trial. The long-term goal of this investigation is to systematically evaluate
the effect of tadalafil therapy on exercise performance, quality of life, and delay of
functional deterioration in patients with single ventricle physiology.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Patients who have undergone the Fontan procedure (regardless of type of Fontan
connection or presence or absence of a fenestration)
- Age 8.0 to 35.0 years
- Stable clinical condition over the last 3 months (i.e. No change in medication,
treatments, or development of new symptoms)
- Ability to perform exercise testing
- Consent and assent (as appropriate to participate in the study after receiving
information concerning procedures, risks, and possible clinical benefits) o Patients
will be enrolled without regard to gender, race, and ethnicity. All patients meeting
study eligibility will be approached for consent.
Exclusion Criteria:
- Severe heart failure (New York Heart Association functional class III or IV)
- Presence of liver or renal dysfunction based on the latest lab test results
- Presence of hearing or visual deficit
- Transcutaneous arterial blood oxygen saturation (SaO2) <80% at rest
- History of echocardiographic, MRI, or angiographic evidence of Fontan pathway
obstruction
- History of exercise-induced life-threatening arrhythmias or unstable rhythm(i.e.
atrial flutter)
- Known or suspected pregnancy. Females in the reproductive age group will be screened
for pregnancy using serum beta hCG prior to administering study drug.
- Patients on open label sildenafil or tadalafil
|
| NCT ID: |
|
NCT01291069 |
| Primary Contact: |
|
Principal Investigator
Shaji C. Menon, MD
University of Utah
Linda M. Lambert, APRN
Phone: 801 662 5573
Email: linda.lambert@imail.org
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Salt lake City, Utah 84113
United States
Shaji C. Menon, MD
Phone: 801-662-5400
Email: shaji.menon@imail.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|